AGM Schedule

  • Meeting: 37th Annual General Meeting
  • Day & Date: Tuesday, 4th August 2026
  • Time: 11:00 A.M. IST
  • Mode: Through Video Conferencing (VC)/Other Audio-Visual Means (OAVM)
  • E-voting Period: Saturday, 1st August 2026 (09:00 a.m.) to Monday, 3rd August 2026 (05:00 p.m.) via NSDL
  • Cut-off date for e-voting eligibility: Tuesday, 28th July 2026
  • Record Date for Dividend: Thursday, 23rd July 2026

Business to be Transacted

ORDINARY BUSINESSES

1. Adoption of Financial Statements

To receive, consider, and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the Financial Year ended 31st March 2026, together with the Reports of the Board of Directors and Auditors thereon.

2. Re-appointment of Director

To re-appoint Mr. Ajay Shrirang Kandelkar (DIN: 10773491) as a director who retires by rotation. He was initially appointed on 13th September 2024. The Board recommends his re-appointment based on performance evaluation and the recommendation of the nomination and remuneration committee.

3. Declaration of Dividend

To declare a Dividend of ₹1.50 (Rupees One and fifty paisa only) per Equity Share (150%) of face value ₹1/- each for FY 2025-26.

SPECIAL BUSINESSES

4. Ratification of Cost Auditor Remuneration

To ratify the remuneration payable to M/s. Chetan Gandhi & Associates, Cost Accountants, for conducting the audit of cost records for FY 2026-27. The remuneration is set at ₹50,000/- plus applicable GST and out-of-pocket expenses.

5. Appointment of Secretarial Auditor

To appoint Mr. Hemang Mehta (Proprietor of H. M. Mehta & Associates, Membership No. F4965) as Secretarial Auditor for a term of 5 consecutive years from FY 2026-27 to FY 2030-31. The remuneration for FY 2026-27 is set at ₹1,75,000/- plus applicable GST and out-of-pocket expenses.

6. Appointment of Director

To appoint Mr. Milin Mehta (DIN: 01297508) as a Director (Non-Executive & Non-Independent). He was appointed as an Additional Director by the Board on 26th June 2026.

7. Ratification of ESOP Scheme 2025

To ratify the "Sudeep Pharma Employee Stock Option Scheme 2025" (ESOP 2025), which was originally approved by shareholders on 9th May 2025 and amended prior to the IPO. The scheme allows for the grant of up to 21,70,014 Options, convertible into an equal number of equity shares of ₹1/- each.

8. ESOP Grant to Subsidiary Employees

To approve the grant of employee stock options under ESOP 2025 to eligible employees of the company's subsidiary companies.

9. ESOP Grant to Group/Associate Company Employees

To approve the grant of employee stock options under ESOP 2025 to eligible employees of the company's group companies, including associate companies.

10. Change in Director Remuneration

To approve an upward revision in the remuneration of Mr. Ajay Shrirang Kandelkar, Whole Time Director, effective 1st April 2026. The new remuneration is:

  • Salary: ₹1,14,97,600 per annum
  • Perquisites: Company Driver and Fuel reimbursement
  • Commission: Additional commission based on net profits, as determined by the Board

11. Adoption of New Articles of Association

To adopt a new set of Articles of Association in conformity with the Companies Act, 2013, replacing the existing Articles. This is required per a Waiver Cum Amendment Agreement dated 17th June 2025.

Financial Impact

  • Dividend Outflow: The dividend declaration of ₹1.50 per share will result in a cash outflow from profits.
  • Director Remuneration: The revised remuneration for Mr. Ajay Kandelkar will increase the company's annual employee benefit expense by ₹1,14,97,600 in salary plus perquisites and potential commission.
  • Auditor Remuneration: The cost auditor remuneration is capped at ₹50,000, and the secretarial auditor remuneration is set at ₹1,75,000 for FY 2026-27.
  • ESOP Impact: The potential issuance of up to 21,70,014 new equity shares upon exercise of options would lead to dilution of existing shareholding. The financial impact of ESOP accounting will be recognized as per applicable accounting standards.

Voting Information

The company is providing e-Voting facilities through NSDL. The remote e-voting period starts on 1st August 2026 and ends on 3rd August 2026. Members can also vote during the AGM.

Dividend Payment Details

  • The dividend will be paid to shareholders on the register as of the Record Date, Thursday, 23rd July 2026.
  • The company will deduct tax at source on dividend payments as per the Income Tax Act.
  • Shareholders are urged to update their bank account details and email IDs with their depository participants to receive dividends via ECS.

Documents Availability

The Notice and Integrated Annual Report 2025-26 are available on the company's website (https://www.sudeeppharma.com/) and the websites of the stock exchanges. Physical documents are available for inspection at the company's registered office.

Key Dates Summary

  • Record Date for Dividend: 23rd July 2026
  • E-voting Cut-off Date: 28th July 2026
  • E-voting Period: 1st August 2026 (09:00 a.m.) to 3rd August 2026 (05:00 p.m.)
  • AGM Date: 4th August 2026 (11:00 a.m.)